Valve and implant compared for refractory glaucoma

Article

Patients with refractory glaucoma in whom a proprietary glaucoma implant was placed needed significantly less adjunctive medication to experience success in treatment compared with those who received a proprietary glaucoma valve. However, fewer of those in the latter group had serious postoperative complications, according to recently published 3-year outcomes.

Patients with refractory glaucoma in whom a proprietary glaucoma implant (Baerveldt, Abbott Medical Optics) was placed needed significantly less adjunctive medication to experience success in treatment compared with those who received a proprietary glaucoma valve (Ahmed FP7, New World Medical). However, fewer of those in the latter group had serious postoperative complications, according to 3-year outcomes reported in a study published online by Ophthalmology.

The multicentre, randomized, controlled clinical trial included 133 participants in the implant group and 143 in the valve group. Participants were aged 18 to 85 years and had IOP ≥18 mmHg. They were randomly assigned to receive the implant or valve.

The main outcomes at 3 years as measured by researchers from the UK, the US and Brazil:

  • IOP. The investigators found that IOP (mean ± standard deviation) was 14.3 ± 4.7 mmHg in the valve group and 13.1 ± 4.5 mmHg in the implant group.
  • VA. The mean change in the logarithm of the minimum angle of resolution VA was similar in both treatment groups.
  • Supplemental medical therapy. Participants were taking 2.0 ± 1.4 glaucoma medications in the valve group and 1.5 ± 1.4 in the implant group.
  • Complications. Postoperative complications associated with reoperation or vision loss of >2 Snellen lines occurred in 24 patients in the valve group and 38 patients in the implant group.
  • Failure (defined as IOP >21 mmHg or not reduced by 20% from baseline, IOP

For more information, you can access the abstract here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.